Ipamorelin
A selective growth-hormone secretagogue that stimulates pituitary GH release with minimal cortisol or prolactin elevation.
Written by Anthivera EditorialPending medical review
Updated Regulatory status verified May 1, 2026
Research-only
Relevance for women
A selective growth-hormone secretagogue with a cleaner side-effect profile than older agents. Studied for body composition, sleep, and recovery. Compounding status under review in 2026.
Featured in focus this week
No peptide cleared the research-mention floor (100). Falling back to deterministic week-of-year rotation: ISO week 27 → ipamorelin.
Week of 2026-06-29 · editorial rotation
Where the evidence sits
Anthivera’s calibrated five-tier scale — what the strongest evidence on Ipamorelin actually supports today.
- Preclinical
- Limited clinicalIpamorelin
- Multiple human studies
- Phase 3
- FDA-approved
Limited clinical: Small open-label or case-report data in humans.
Regulatory timeline
Dated milestones in Ipamorelin’s U.S. regulatory path.
Late 2023
Placed on FDA Category 2 (do-not-compound list), restricting compounding-pharmacy access.
April 23, 2026
Removed from FDA Category 2 compounding list. Removal is NOT the same as Category 1 status or FDA approval.
July 23–24, 2026
Pharmacy Compounding Advisory Committee (PCAC) review scheduled to evaluate inclusion on the 503A Bulks List.
Questions to bring to a consult
- 01What evidence is there for Ipamorelin in women specifically — and does that include perimenopausal or postmenopausal cohorts?
- 02What is the current FDA regulatory status, and which compounding pharmacy will my prescription go through?
- 03What baseline labs do you require before starting, and how often do you monitor?
- 04What are the realistic timelines and what does “not working for you” look like in practice?
Articles on Ipamorelin
Peptides and Sleep: What Women Should Know
Sleep disruption is one of the most common perimenopause complaints. Here's what's discussed about GH-axis peptides and sleep — and what the evidence actually supports.
Peptides for Perimenopause: What the Research Actually Says
A grounded look at peptides discussed for perimenopause — GH-axis peptides, BPC-157, kisspeptin, collagen, GLP-1 — and where the evidence is strong versus preliminary, with the current 2026 regulatory and safety picture.
Providers that offer Ipamorelin
- 4.6/5
Solace MD
Higher price band, faster shipping, more personal care — the right fit if cost isn't the primary constraint.
- 4.0/5
Canopy Telehealth Clinic
Broad catalog and broad geographic reach; longer intake process but thorough lab work.
See the full provider comparison for all peptides side by side.